FDA staff says Guardant's test may fail to detect some pre-cancerous tumors

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised concerns that Guardant Health's (GH.O) experimental blood test for a cancer of colon or rectum may fail to detect some types of tumors that can later become cancerous.